The Second Infusion is live. Your infusion changed your life. Your second one changes hers.
Give the second infusion →Impact
Every number on this page comes from a peer-reviewed abstract presented at the American Society of Hematology or from the allocation the Foundation publishes on this site. Nothing here is an estimate, a projection or a round number.
The numbers
Two years of outcomes, published and peer-reviewed, from the clinical partners that deliver the Foundation's model.
5,000+
women treated since 2020
Fem Network clinical data
2,971
infusions to 1,383 pregnant patients
ASH 2023, Abstract 2381
7,246
infusions across 3,076 patients in two years
ASH 2023, Abstract 2314
0
adverse events that affected a pregnancy
ASH 2023, Abstract 2381
94%
reported improvement in one or more symptoms
ASH 2023, Abstract 2314
1.2 g/dL
average hemoglobin increase after treatment
ASH 2023, Abstract 2381
9 days
average from consult to infusion
ASH 2023, Abstract 2314
4.5%
overall reaction rate, almost all mild
ASH 2023, Abstract 2314
Where the money goes
The allocation is published on this site, and every gift is tracked against it.
40%
Expand mobile and clinic-based treatments
20%
Direct treatment fund
20%
Education and national awareness
10%
Research and clinical trials
10%
Infrastructure and staffing
Bring mobile and clinic-based testing and treatment to more communities
Cover the full cost of care for uninsured women
Launch a national awareness campaign aimed at schools, athletes and OB/GYNs
Fund research to drive policy change and clinical guidelines
Strengthen the infrastructure to scale impact sustainably
The evidence
The Foundation does not run its own trials. It funds a model whose results are submitted to the American Society of Hematology and can be read by anyone.
ASH 2023 · Abstract 2314
Outcomes of a telemedicine iron-infusion model
7,246 infusions across 3,076 patients over two years. Nine days from televisit to infusion on average. 94% of patients reported improvement in at least one symptom. Reaction rate 4.5%, almost all mild.
ASH 2023 · Abstract 2381
IV iron in pregnancy
2,971 infusions to 1,383 pregnant patients. Average hemoglobin rise of 1.2 g/dL. No adverse event that affected a pregnancy.
Read the abstract →ASH 2026
Cost-effectiveness of IV iron
IV iron is cost-effective at $28,600 per quality-adjusted life year and should be considered first-line treatment for iron deficiency in women.
Read the abstract →How we report
Donors and Iron Circle members receive an impact receipt: women screened, seen and treated, and what it cost.
Every year
The allocation and the year's figures are published on this page, in full, with sources.
Every result
Clinical outcomes are submitted for peer review before they appear here. If we cannot source a number, we do not publish it.
Every figure on this page was paid for by someone. The next one can be yours.
Sources
01
ASH 2023, Abstract 2314. Outcomes of a telemedicine iron-infusion model: 7,246 infusions, 3,076 patients, nine days from televisit to infusion, 94% symptom improvement, 4.5% reaction rate.
02
ASH 2023, Abstract 2381. IV iron in pregnancy: 2,971 infusions to 1,383 patients, 1.2 g/dL average hemoglobin increase, no adverse event affecting a pregnancy.
03
American Society of Hematology, 2026. IV iron cost-effective at $28,600 per quality-adjusted life year.
04
Fem Network clinical data. More than 5,000 women treated since 2020.
05
femfoundation.org. Published allocation 40 / 20 / 20 / 10 / 10 of the $10 million campaign goal.